Zyvox, Synercid Launches Indicate Market Receptivity To New Antibiotics

Pharmacia's Zyvox (linezolid) sales of $19 mil. in the two-and-a-half months from its U.S. commercial launch in mid-April until the end of the June 30 quarter put the product $4 mil. ahead of sales of the Aventis antibiotic Synercid (quinipristin/dalfopristin) in the second quarter of 2000.